On September 9, 2020 Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Biomica, SEP 9, 2020, https://www.prnewswire.com/news-releases/biomica-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126264.html [SID1234564887]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Elran Haber, CEO of Biomica, will provide an overview of the Company’s business during a live presentation, scheduled for Wednesday, September 16, 12:30 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.